pillbase.ru

Insulin glargine U-300 Max

Active substance: insulin glargine

INJECTION, SOLUTION · INSULIN GLARGINE 300 [iU]/mL

United StatesActive

Marketing holder: Sanofi-Aventis U.S. LLC

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 7
  • Abasaglar (previously Abasria)
    insulin glargine
    EMEA/H/C/002835
    Eli Lilly Nederland B.V.
  • Lantus
    insulin glargine
    EMEA/H/C/000284
    sanofi-aventis Deutschland GmbH
  • Ondibta
    insulin glargine
    EMEA/H/C/006136
    Sandoz GmbH
  • Semglee
    insulin glargine
    EMEA/H/C/004280
    Biosimilar Collaborations Ireland Limited
  • Suliqua
    insulin glargine, lixisenatide
    EMEA/H/C/004243
    Sanofi Winthrop Industrie
All products in this country (7)
Registration
Registration number
0955-2900
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 0955-2900 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 0955-2900 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 0955-2900 · Verified 2026-10-09 · open in source